NEW YORK, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Milestone Pharmaceuticals Inc. ("Milestone" or the "Company") (NASDAQ:MIST) on behalf of Milestone stockholders. Our investigation concerns whether Milestone has violated the federal securities laws and/or engaged in other unlawful business practices.
Click here to participate in the action.
On December 26, 2023, before the market opened, Milestone Pharmaceuticals, Inc. announced that it had received a Refuse to File ("RFT") letter from the U.S. Food and Drug Administration ("FDA") for ...